

# Ali A. Rizvi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4173967/publications.pdf>

Version: 2024-02-01

97  
papers

2,235  
citations

218381

26  
h-index

264894

42  
g-index

99  
all docs

99  
docs citations

99  
times ranked

2811  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inclisiran: a small interfering RNA strategy targeting PCSK9 to treat hypercholesterolemia. Expert Opinion on Drug Safety, 2022, 21, 9-20.	1.0	29
2	Correlations between Diabetes Mellitus Self-Care Activities and Glycaemic Control in the Adult Population: A Cross-Sectional Study. Healthcare (Switzerland), 2022, 10, 174.	1.0	17
3	Experimental and Emerging Free Fatty Acid Receptor Agonists for the Treatment of Type 2 Diabetes. Medicina (Lithuania), 2022, 58, 109.	0.8	3
4	Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections. Expert Opinion on Drug Safety, 2022, 21, 291-293.	1.0	6
5	The Emerging Role of Dual GLP-1 and GIP Receptor Agonists in Glycemic Management and Cardiovascular Risk Reduction. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2022, Volume 15, 1023-1030.	1.1	20
6	Safety and Outcomes of Intravitreal Aflibercept in Diabetic Macular Edema – A Systematic Review. Current Pharmaceutical Design, 2022, 28, 1758-1768.	0.9	3
7	The Relationship between COVID-19 and Hypothalamic–Pituitary–Adrenal Axis: A Large Spectrum from Glucocorticoid Insufficiency to Excess – The CAPISCO International Expert Panel. International Journal of Molecular Sciences, 2022, 23, 7326.	1.8	30
8	Liraglutide Reduces Carotid Intima-Media Thickness by Reducing Small Dense Low-Density Lipoproteins in a Real-World Setting of Patients with Type 2 Diabetes: A Novel Anti-Atherogenic Effect. Diabetes Therapy, 2021, 12, 261-274.	1.2	41
9	Novel Therapeutic Approaches to Managing Atherosclerotic Risk. International Journal of Molecular Sciences, 2021, 22, 4633.	1.8	23
10	Genetic and Epigenetic Biomarkers for Diagnosis, Prognosis and Treatment of Metabolic Syndrome. Current Pharmaceutical Design, 2021, 27, 3729-3740.	0.9	9
11	The Evolving Role of Fetuin-A in Nonalcoholic Fatty Liver Disease: An Overview from Liver to the Heart. International Journal of Molecular Sciences, 2021, 22, 6627.	1.8	18
12	Diabetes and COVID-19: A Tale of 2 Pandemics. Journal of Cardiovascular Pharmacology, 2021, 78, e1-e2.	0.8	5
13	The role of GLP-1 receptor agonists during COVID-19 pandemic: a hypothetical molecular mechanism. Expert Opinion on Drug Safety, 2021, 20, 1309-1315.	1.0	15
14	Endocrinology in the Time of COVID-19: A Rapid Evolution of Knowledge and Care. Medicina (Lithuania), 2021, 57, 805.	0.8	4
15	Novel molecular markers of cardiovascular disease risk in type 2 diabetes mellitus. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2021, 1867, 166148.	1.8	14
16	Reconnoitering the Role of Long-Noncoding RNAs in Hypertrophic Cardiomyopathy: A Descriptive Review. International Journal of Molecular Sciences, 2021, 22, 9378.	1.8	7
17	Metabolic Syndrome: From Molecular Mechanisms to Novel Therapies. International Journal of Molecular Sciences, 2021, 22, 10038.	1.8	12
18	Use of Novel Antidiabetic Agents in Patients with Type 2 Diabetes and COVID-19: A Critical Review. Diabetes Therapy, 2021, 12, 3037-3054.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Lipoproteins and Cardiovascular Disease: An Update on the Clinical Significance of Atherogenic Small, Dense LDL and New Therapeutical Options. <i>Biomedicines</i> , 2021, 9, 1579.	1.4	26
20	Glycemic Variability, Glycated Hemoglobin, and Cardiovascular Complications: Still a Dilemma in Clinical Practice. <i>Advances in Therapy</i> , 2021, , 1.	1.3	1
21	Cardiometabolic Alterations in the Interplay of COVID-19 and Diabetes: Current Knowledge and Future Avenues. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12311.	1.8	7
22	Promoting a Syndemic Approach for Cardiometabolic Disease Management During COVID-19: The CAPISCO International Expert Panel. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787761.	1.1	38
23	Diabetes and COVID-19: What 2 Years of the Pandemic Has Taught Us. <i>Metabolic Syndrome and Related Disorders</i> , 2021, , .	0.5	5
24	Liraglutide Increases Serum Levels of MicroRNA-27b, -130a and -210 in Patients with Type 2 Diabetes Mellitus: A Novel Epigenetic Effect. <i>Metabolites</i> , 2020, 10, 391.	1.3	9
25	Daily Use of Extra Virgin Olive Oil with High Oleocanthal Concentration Reduced Body Weight, Waist Circumference, Alanine Transaminase, Inflammatory Cytokines and Hepatic Steatosis in Subjects with the Metabolic Syndrome: A 2-Month Intervention Study. <i>Metabolites</i> , 2020, 10, 392.	1.3	34
26	Cardiovascular outcomes trials with incretin-based medications: a critical review of data available on GLP-1 receptor agonists and DPP-4 inhibitors. <i>Metabolism: Clinical and Experimental</i> , 2020, 111, 154343.	1.5	36
27	Pasta Supplemented with <i>Opuntia ficus-indica</i> Extract Improves Metabolic Parameters and Reduces Atherogenic Small Dense Low-Density Lipoproteins in Patients with Risk Factors for the Metabolic Syndrome: A Four-Week Intervention Study. <i>Metabolites</i> , 2020, 10, 428.	1.3	17
28	The efficacy and safety of dipeptidyl peptidase-4 inhibitors compared to other oral glucose-lowering medications in the treatment of type 2 diabetes. <i>Metabolism: Clinical and Experimental</i> , 2020, 109, 154295.	1.5	18
29	Impact of Glucose-Lowering Medications on Cardiovascular and Metabolic Risk in Type 2 Diabetes. <i>Journal of Clinical Medicine</i> , 2020, 9, 912.	1.0	27
30	Incretin-Based Therapies Role in COVID-19 Era: Evolving Insights. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2020, 25, 494-496.	1.0	25
31	Diabetes and the COVID-19 Pandemic: How Insights from Recent Experience Might Guide Future Management. <i>Metabolic Syndrome and Related Disorders</i> , 2020, 18, 173-175.	0.5	79
32	Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study. <i>Diabetes Research and Clinical Practice</i> , 2019, 149, 163-169.	1.1	30
33	Microvascular and macrovascular effects of liraglutide. <i>International Journal of Cardiology</i> , 2019, 286, 17-18.	0.8	3
34	Future perspectives of the pharmacological management of diabetic dyslipidemia. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 129-143.	1.3	29
35	Visual Vignette. <i>Endocrine Practice</i> , 2018, 24, 1110.	1.1	0
36	GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2018, 1864, 2814-2821.	1.8	104

#	ARTICLE	IF	CITATIONS
37	Lymphedema following breast cancer: The importance of surgical methods and obesity. <i>Frontiers in Women's Health</i> , 2018, 3, 195-199.	0.1	9
38	Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 613-614.	2.2	5
39	Thyroid Dysfunction in Torsades de Pointes. <i>JAMA Internal Medicine</i> , 2017, 177, 1693.	2.6	1
40	ADDRESSING HYPERTENSION IN THE PATIENT WITH TYPE 2 DIABETES MELLITUS: PATHOGENESIS, GOALS, AND THERAPEUTIC APPROACH. <i>European Medical Journal Diabetes</i> , 2017, 5, 84-92.	4.0	10
41	An Overview of Insulin Pumps and Glucose Sensors for the Generalist. <i>Journal of Clinical Medicine</i> , 2016, 5, 5.	1.0	92
42	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. <i>Cardiovascular Diabetology</i> , 2016, 15, 162.	2.7	98
43	Giant Intracranial Aneurysm Masquerading in the Sella. <i>American Journal of the Medical Sciences</i> , 2016, 351, 119.	0.4	2
44	Incretins, Pregnancy, and Gestational Diabetes. <i>Current Pharmaceutical Biotechnology</i> , 2016, 17, 597-602.	0.9	13
45	TREATMENT OF TYPE 2 DIABETES WITH BIPHASIC INSULIN ANALOGUES. <i>European Medical Journal Diabetes</i> , 2016, 4, 74-83.	4.0	7
46	The evolution of an integrated ultrasound curriculum (iUSC) for medical students: 9-year experience. <i>The Ultrasound Journal</i> , 2015, 7, 18.	2.0	129
47	Hypercalcemia Associated with Calcium Supplement Use: Prevalence and Characteristics in Hospitalized Patients. <i>Journal of Clinical Medicine</i> , 2015, 4, 414-424.	1.0	16
48	Dapagliflozin therapy in type-2 diabetes: current knowledge and future perspectives. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 281-284.	0.9	6
49	Liraglutide improves carotid intima-media thickness in patients with type 2 diabetes and non-alcoholic fatty liver disease: an 8-month prospective pilot study. <i>Expert Opinion on Biological Therapy</i> , 2015, 15, 1391-1397.	1.4	36
50	Liraglutide Reduces Oxidative Stress And Restores Heme Oxygenase-1 and Ghrelin Levels in Patients with Type 2 Diabetes: A Prospective Pilot Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 603-606.	1.8	84
51	Gestational Diabetes and the Metabolic Syndrome: Can Obesity and Small, Dense Low Density Lipoproteins be Key Mediators of this Association?. <i>Current Pharmaceutical Biotechnology</i> , 2014, 15, 38-46.	0.9	11
52	Impact of Clinical and Therapeutic Factors on Incident Cardiovascular and Cerebrovascular Events in a Population-Based Cohort of HIV-Infected and Non-HIV-Infected Adults. <i>Clinical Cardiology</i> , 2014, 37, 517-522.	0.7	27
53	Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents. <i>Metabolic Syndrome and Related Disorders</i> , 2014, 12, 1-10.	0.5	12
54	Liraglutide decreases carotid intima-media thickness in patients with type 2 diabetes: 8-month prospective pilot study. <i>Cardiovascular Diabetology</i> , 2014, 13, 49.	2.7	86

#	ARTICLE	IF	CITATIONS
55	Diabetic Ketoalkalosis in Children and Adults. Southern Medical Journal, 2014, 107, 6-10.	0.3	4
56	Incretin-Based Therapies, Glucometabolic Health and Endovascular Inflammation. Current Pharmaceutical Design, 2014, 20, 4953-4960.	0.9	27
57	Uric Acid Metabolism in Pre-hypertension and the Metabolic Syndrome. Current Vascular Pharmacology, 2014, 12, 572-585.	0.8	16
58	The effects of liraglutide on glucose, inflammatory markers and lipoprotein metabolism: current knowledge and future perspective. Clinical Lipidology, 2013, 8, 173-181.	0.4	24
59	Non-glycemic effects of pioglitazone and incretin-based therapies. Expert Opinion on Therapeutic Targets, 2013, 17, 739-742.	1.5	10
60	Association of Clinical and Therapeutic Factors with Incident Dyslipidemia in a Cohort of Human Immunodeficiency Virus-Infected and Non-Infected Adults: 1994-2011. Metabolic Syndrome and Related Disorders, 2013, 11, 417-426.	0.5	11
61	A Review of the Cardiovascular and Anti-Atherogenic Effects of Ghrelin. Current Pharmaceutical Design, 2013, 19, 4953-4963.	0.9	22
62	Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?. Current Pharmaceutical Design, 2013, 19, 3858-3868.	0.9	41
63	The Role of Elevated Growth Hormone on the Increased Atherosclerosis in Patients With Acromegaly. Angiology, 2012, 63, 492-494.	0.8	3
64	Oxidative stress and small, dense low-density lipoproteins: current and future perspectives. Expert Review of Endocrinology and Metabolism, 2012, 7, 415-417.	1.2	4
65	Normocalcemic Primary Hyperparathyroidism-Characteristics and Clinical Significance of an Emerging Entity. American Journal of the Medical Sciences, 2012, 343, 163-166.	0.4	13
66	Prevalence and Impact of Initial Misclassification of Pediatric Type 1 Diabetes Mellitus. Southern Medical Journal, 2012, 105, 513-517.	0.3	18
67	The Risk of Developing Type 2 Diabetes Mellitus Associated With Psychotropic Drug Use in Children and Adolescents. primary care companion for CNS disorders, The, 2012, 14, .	0.2	10
68	Visual Vignette. Endocrine Practice, 2012, 18, 426-426.	1.1	1
69	Vitamin D Deficiency in Patients with Congestive Heart Failure. Southern Medical Journal, 2011, 104, 325-330.	0.3	19
70	Headache, Pituitary Lesion and Panhypopituitarism in a Pregnant Woman: Tumor, Apoplexy or Hypophysitis?. American Journal of the Medical Sciences, 2011, 342, 247-249.	0.4	19
71	Sustained Remission with the Kinase Inhibitor Sorafenib in Stage IV Metastatic Adrenocortical Carcinoma. Endocrine Practice, 2010, 16, 441-445.	1.1	19
72	Hypertension, Obesity, and Inflammation: The Complex Designs of a Deadly Trio. Metabolic Syndrome and Related Disorders, 2010, 8, 287-294.	0.5	28

#	ARTICLE	IF	CITATIONS
73	Perioperative Management of Diabetes and Hyperglycemia in Patients Undergoing Orthopaedic Surgery. <i>Journal of the American Academy of Orthopaedic Surgeons</i> , The, 2010, 18, 426-435.	1.1	83
74	Nutritional challenges in the elderly with diabetes. <i>International Journal of Diabetes Mellitus</i> , 2009, 1, 26-31.	0.6	30
75	The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. <i>Acta Diabetologica</i> , 2009, 46, 1-11.	1.2	27
76	Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2009, 18, 1495-1503.	1.9	73
77	Cytokine Biomarkers, Endothelial Inflammation, and Atherosclerosis in the Metabolic Syndrome: Emerging Concepts. <i>American Journal of the Medical Sciences</i> , 2009, 338, 310-318.	0.4	99
78	Impact of Comprehensive Diabetes Specialty Care in the Management of Older Adults with Stage 3 or 4 Nephropathy. <i>Southern Medical Journal</i> , 2009, 102, 985.	0.3	3
79	46, XX Man with SRY Gene Translocation: Cytogenetic Characteristics, Clinical Features and Management. <i>American Journal of the Medical Sciences</i> , 2008, 335, 307-309.	0.4	21
80	Vitamin D Levels in Patients Seen in the Diabetes Unit of an Academic Medical Center. <i>Southern Medical Journal</i> , 2008, 101, 1069.	0.3	3
81	Management of Diabetes in Older Adults. <i>American Journal of the Medical Sciences</i> , 2007, 333, 35-47.	0.4	32
82	“Thyrotoxic Psychosis” Associated With Subacute Thyroiditis. <i>Southern Medical Journal</i> , 2007, 100, 837-840.	0.3	11
83	Care of patients with diabetes who are undergoing surgery. <i>JAAPA: Official Journal of the American Academy of Physician Assistants</i> , 2007, 20, 36.	0.1	0
84	The Use of Premixed Insulin Analogues in the Treatment of Patients with Type 2 Diabetes Mellitus: Advantages and Limitations. <i>Insulin</i> , 2007, 2, 68-79.	0.2	9
85	PARASELLAR MENINGIOMA RESEMBLING A PITUITARY TUMOR. <i>Endocrine Practice</i> , 2007, 13, 86-88.	1.1	0
86	Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome and type 2 diabetes. <i>Chinese Medical Journal</i> , 2007, 120, 1918-1924.	0.9	9
87	Inflammation markers as mediators of vasculo-endothelial dysfunction and atherosclerosis in the metabolic syndrome. <i>Chinese Medical Journal</i> , 2007, 120, 1918-24.	0.9	2
88	Severe Primary Hypothyroidism Manifesting with Torsades De Pointes. <i>American Journal of the Medical Sciences</i> , 2006, 331, 154-156.	0.4	64
89	Levofloxacin-Induced Hypoglycemia in a Nondiabetic Patient. <i>American Journal of the Medical Sciences</i> , 2006, 331, 334-335.	0.4	25
90	Assessment and monitoring of glycemic control in primary diabetes care: Monitoring techniques, record keeping, meter downloads, tests of average glycemia, and point-of-care evaluation. <i>Journal of the American Academy of Nurse Practitioners</i> , 2006, 18, 11-21.	1.4	7

#	ARTICLE	IF	CITATIONS
91	The Role of Inflammation in Diabetes and Its Complications. Southern Medical Journal, 2006, 99, 8-9.	0.3	0
92	Current trends in diabetes management. JAAPA: Official Journal of the American Academy of Physician Assistants, 2005, 18, 23-29.	0.1	1
93	Hypocalcemia and Parathyroid Function in Metastatic Prostate Cancer. Endocrine Practice, 2005, 11, 254-258.	1.1	11
94	Eliminating Inpatient Sliding-Scale Insulin: A Reeducation Project With Medical House Staff: Response to Baldwin et al.. Diabetes Care, 2005, 28, 2336-2336.	4.3	1
95	Some Clues and Pitfalls in the Diagnosis of Acromegaly. Endocrine Practice, 2004, 10, 348-352.	1.1	6
96	Type 2 Diabetes: Epidemiologic Trends, Evolving Pathogenic Concepts, and Recent Changes in Therapeutic Approach. Southern Medical Journal, 2004, 97, 1079-1087.	0.3	26
97	Current and emerging drugs for the treatment of atherosclerosis: the evidence to date. Expert Review of Cardiovascular Therapy, 0, , 1-13.	0.6	1